Cover Image
市場調查報告書

抗菌藥的全球市場:2015∼2019年

Global Antibacterial Drugs Market 2015-2019

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 345157
出版日期 內容資訊 英文 116 Pages
訂單完成後即時交付
價格
Back to Top
抗菌藥的全球市場:2015∼2019年 Global Antibacterial Drugs Market 2015-2019
出版日期: 2015年11月11日 內容資訊: 英文 116 Pages
簡介

抗菌藥是抗生素的同義語,是消滅細菌或阻礙細菌增生治療由細菌引起的感染疾病的化學化合物。雖然細菌、真菌、寄生蟲等微生物有效果,不過對病毒無效。預計全球抗菌藥市場2014∼2019年以年複合成長率1.06%擴大。

本報告提供全球抗菌藥市場相關調查、各地區趨勢、今後的市場成長前景、2019年的市場規模預測、市場成長的課題、主要供應商趨勢等彙整資料。

第1章 摘要整理

第2章 本報告的範圍

第3章 市場調查方法

第4章 簡介

第5章 抗菌藥:概要

  • 簡介
  • 作用機制
  • 抗生素使用的一般原則
  • 臨床的使用
  • 流行病學

第6章 開發平台分析

第7章 對抗菌藥的抗性

第8章 美國的抗生素使用相關法規

第9章 市場環境

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第10章 各化學等級市場區隔

  • β-內醯胺
  • 氨基糖苷類
  • 酰胺醇類
  • 奎諾酮類抗生素(Quinolones)
  • 葉酸拮抗劑
  • 四環素
  • 其他

第11章 各藥物來源市場區隔

  • 天然
  • 半合成
  • 合成

第12章 各作用機制市場區隔

  • 靜菌性
  • 殺菌性

第13章 各作用範圍市場區隔

  • 廣域
  • 狹階段

第14章 各地區市場區隔

  • 各地區市場區隔
  • 亞太地區
  • 歐洲、中東、非洲
  • 南北美洲

第15章 推動市場的要素

  • 法律規章的特別指定
  • 感染疾病的擴大
  • 意識提升
  • 高齡化

第16章 促進要素的影響

第17章 市場課題

  • 藥物抗性股的開發
  • 專利失效和非專利的加入
  • 研究活動的投資減少

第18章 促進要素與課題的影響

第19章 市場趨勢

  • 策略性聯盟和M&A
  • 患者支援計劃
  • 抗生素研究的資金增加

第20章 供應商環境

  • 競爭模式
  • 2014年的市場佔有率分析
  • 其他值得注意的供應商

第21章 主要供應商分析

  • Allergan
  • GSK
  • Merck
  • Pfizer
  • Sandoz
  • Teva Pharmaceuticals

第22章 附錄

第23章 關於Techvavio

圖表

目錄
Product Code: IRTNTR7883

About antibacterial drugs

Antibacterial drugs are chemical compounds used to treat infections caused by bacteria either by killing or inhibiting the growth of bacteria. The term antibiotic is often used synonymously with an antibacterial. However, antibiotics are agents that work against microorganisms such as bacteria, fungi, and parasites but are not effective against viruses. The term antibiotic was originally coined to refer to any compound of microbial origin, which is antagonistic to the growth of the microbe. Antibacterial acts via various mechanisms such as the inhibition of cell wall synthesis, the inhibition of nucleic acid synthesis, the disruption of the cell membrane, and the inhibition of protein synthesis. They can be bacteriostatic or bactericidal in nature, i.e., they either block vital processes in bacteria, kill the bacteria, or halt them from growing. Antibiotics that affect a wide range of bacteria are called broad-spectrum antibiotics (e.g., amoxicillin and gentamicin). Antibiotics that affect only a few types of bacteria are called narrow spectrum antibiotics (e.g., penicillin).

Technavio's analysts forecast the global antibacterial drugs market to grow at a CAGR of 1.06% over the period 2014-2019.

Covered in this report

In this report, Technavio covers the present scenario and growth prospects of the global antibacterial drugs market for 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various prescription drugs along with the generic drugs used for the treatment of various infectious diseases caused by the different strains of bacteria. The various classes of antibacterial drug included in this report are beta-lactams, macrolides, aminoglycosides, phenicols, quinolones, folate antagonists, tetracyclines, and other miscellaneous agents, which include glycopeptides, nitroimidazoles, lincosamides, lipopeptides, nicotinic acid derivatives, and polypeptide antibiotics.

Technavio's report, Global Antibacterial Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and EMEA; it also covers the landscape of the global antibacterial drugs market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key regions

  • Americas
  • APAC
  • EMEA

Key vendors

  • Allergan
  • GlaxoSmithKline
  • Merck
  • Novartis
  • Pfizer
  • Teva Pharmaceuticals

Other Prominent Vendors

  • Abbott
  • Achaogen
  • Actelion
  • AmpliPhi Biosciences
  • Aspen Pharmacare
  • Astellas
  • AstraZeneca
  • Aurobindo Pharma
  • Baxter
  • Basilea Pharmaceuticals
  • Bayer
  • Biocon
  • Bristol-Myers Squibb
  • Cempra
  • Cipher Pharmaceuticals
  • Corden Pharma
  • Cornerstone Therapeutics
  • Eli Lilly
  • Exoxemis
  • F. Hoffmann-La Roche
  • Flynn Pharma
  • Hospira
  • Incepta Pharmaceuticals
  • InSite Vision
  • Insmed Incorporated
  • Johnson & Johnson
  • KaloBios Pharmaceuticals
  • Kyorin Pharmaceutical
  • Lupin Pharmaceuticals
  • Lytix Biopharma
  • Melinta Therapeutics
  • Mylan
  • Nektar
  • Orchid Pharma
  • Par Pharmaceutical
  • Paratek Pharmaceuticals
  • Pernix Therapeutics
  • PTC Therapeutics
  • RedHill Biopharma
  • Sagent Pharmaceuticals
  • Sanofi
  • Shionogi
  • Starpharma
  • Sun Pharmaceutical
  • Symbiomix
  • Takeda Pharma
  • Tetraphase Pharmaceuticals
  • Theravance Biopharma
  • The Medicines Company
  • Valneva
  • Wockhardt Global Solutions

Key market driver

  • Special regulatory designations
  • For a full, detailed list, view our report

Key market challenge

  • Development of drug-resistant strains
  • For a full, detailed list, view our report

Key market trend

  • Strategic alliances and M&A
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Antibacterial: overview

  • Introduction
  • Mechanism of action
  • General principles for the use of antibiotics
  • Clinical uses
  • Epidemiology

PART 06: Pipeline analysis

  • Zerbaxa
  • Surotomycin
  • MK-3415A
  • Amikacin Inhale
  • CARBAVANCE
  • Eravacycline
  • Plazomicin
  • Delafloxacin
  • Solithromycin
  • VivaGel
  • Arikayce
  • Cadazolid
  • Ozenoxacin

PART 07: Antimicrobial resistance

  • Sources of spread of resistant organisms
  • Initiatives to improve antibiotic innovation

PART 08: Legislation relating to antibiotic use in the US

PART 09: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 10: Market segmentation by chemical class

  • Beta-lactam
  • Macrolides
  • Aminoglycosides
  • Phenicols
  • Quinolones
  • Folate antagonists
  • Tetracyclines
  • Others

PART 11: Market segmentation by drug origin

  • Natural
  • Semisynthetic
  • Synthetic

PART 12: Market segmentation by mechanism of action

  • Bacteriostatic
  • Bactericidal

PART 13: Market segmentation by spectrum of activity

  • Broad spectrum antibiotics
  • Narrow spectrum antibiotics

PART 14: Geographical segmentation

  • Global antibacterial drugs market by geographical segmentation 2014-2019
  • Antibacterial drugs market in APAC
  • Antibacterial drugs market in EMEA
  • Antibacterial drugs market in Americas

PART 15: Market drivers

  • Special regulatory designations
  • Increase in prevalence of infections
  • Increase in awareness
  • Increase in aging population

PART 16: Impact of drivers

PART 17: Market challenges

  • Development of drug resistant strains
  • Patent expiries and generic penetration
  • Decreased investments in research activities

PART 18: Impact of drivers and challenges

PART 19: Market trends

  • Strategic alliances and M&A
  • Patient assistance programs
  • Increased funding on antibiotic research

PART 20: Vendor landscape

  • Competitive scenario
  • Market share analysis 2014
  • Other prominent vendors

PART 21: Key vendor analysis

  • Allergan
  • GSK
  • Merck
  • Pfizer
  • Sandoz
  • Teva Pharmaceuticals

PART 22: Appendix

  • List of abbreviation

PART 23: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Mechanism of action of antibacterial drugs
  • Exhibit 03: General principles involved in the use of antibiotics
  • Exhibit 04: Estimated number of cases for nosocomial infections in US, 2011
  • Exhibit 05: Number of cases for Escherichia coli bacteremia in UK, 2012-2014
  • Exhibit 06: Global antibacterial drugs market: Pipeline portfolio
  • Exhibit 07: Causes of antimicrobial resistance
  • Exhibit 08: Sources of spread of resistant organisms
  • Exhibit 09: Estimated deaths per year caused by AMR in 2050
  • Exhibit 10: Initiatives improving antibiotic innovation
  • Exhibit 11: Legislation relating to antibiotic use in US
  • Exhibit 12: Global antibacterial drugs market 2014-2019 ($ billions)
  • Exhibit 13: Five forces analysis
  • Exhibit 14: Global antibacterial drugs market segmentation by chemical class
  • Exhibit 15: Cephalosporin segmentation by generation of drugs
  • Exhibit 16: Global antibacterial drugs market revenue segmentation by chemical class
  • Exhibit 17: Global antibacterial drugs market segmentation by drug origin
  • Exhibit 18: Global antibacterial drugs market segment by geography 2014
  • Exhibit 19: Antibacterial drugs market revenue by geography 2014-2019 ($ billions)
  • Exhibit 20: Antibacterial drugs market in APAC 2014-2019 ($ billions)
  • Exhibit 21: Antibacterial drugs market in EMEA 2014-2019 ($ billions)
  • Exhibit 22: Antibacterial drugs market in Americas 2014-2019 ($ billions)
  • Exhibit 23: Percentage share of antibacterial drugs market in Americas
  • Exhibit 24: Impact of drivers
  • Exhibit 25: Antibiotic-resistant strains according to the period of development of resistance
  • Exhibit 26: Antibacterial drug approvals by FDA and EMA
  • Exhibit 27: Impact of drivers and challenges
  • Exhibit 28: Allergan: YoY growth and revenue generated from net product sales of anti-infective 2011-2013 ($ millions)
  • Exhibit 29: Allergan: Key takeaways
  • Exhibit 30: GlaxoSmithKline: YoY growth and revenue generated from sales of Augmentin 2011-2014 ($ millions)
  • Exhibit 31: GlaxoSmithKline: Revenue generated from sales of Augmentin by region 2011-2014 ($ millions)
  • Exhibit 32: GlaxoSmithKline: YoY growth and revenue generated from sales of other antibacterials 2011-2013 ($ millions)
  • Exhibit 33: GlaxoSmithKline: Key takeaways
  • Exhibit 34: Merck: YoY growth and revenue generated from sales of Primaxin 2012-2014 ($ millions)
  • Exhibit 35: Merck: YoY growth and revenue generated from sales of Invanz 2012-2014 ($ millions)
  • Exhibit 36: Merck: Key takeaways
  • Exhibit 37: Pfizer: YoY growth and revenue generated from sales of Zyvox 2012-2014 ($ millions)
  • Exhibit 38: Pfizer: YoY growth and revenue generated from sales of Zithromax/Zmax 2012-2014 ($ millions)
  • Exhibit 39: Pfizer: YoY growth and revenue generated from sales of Unasyn 2012-2014 ($ millions)
  • Exhibit 40: Pfizer: YoY growth and revenue generated from sales of Zosyn/Tazocin 2012-2014 ($ millions)
  • Exhibit 41: Pfizer: YoY growth and revenue generated from sales of Sulperazon 2012-2014 ($ millions)
  • Exhibit 42: Pfizer: YoY growth and revenue generated from sales of Tygacil 2012-2014 ($ millions)
  • Exhibit 43: Pfizer: Key takeaways
  • Exhibit 44: Sandoz: Key takeaways
  • Exhibit 45: Teva Pharmaceuticals: Key takeaways
  • Exhibit 46: Allergan: Business segmentation by product revenue 2014
  • Exhibit 47: Allergan: Business segmentation by revenue 2013 and 2014 ($ billions)
  • Exhibit 48: Allergan: Geographical segmentation by revenue 2014
  • Exhibit 49: GSK: Business segmentation by revenue 2014
  • Exhibit 50: GSK: Business segmentation by revenue 2013 and 2014 ($ billions)
  • Exhibit 51: GSK: Geographical segmentation by revenue 2014
  • Exhibit 52: Merck: Business segmentation by revenue 2014
  • Exhibit 53: Merck: Business segmentation by revenue 2013 and 2014 ($ billions)
  • Exhibit 54: Merck: Geographical segmentation by revenue 2014
  • Exhibit 55: Pfizer: Business segmentation by revenue 2014
  • Exhibit 56: Pfizer business segmentation by revenue 2013 and 2014 ($ billions)
  • Exhibit 57: Pfizer: Geographical segmentation by revenue 2014
  • Exhibit 58: Sandoz: Business segmentation by revenue 2014
  • Exhibit 59: Teva Pharmaceuticals: Business segmentation by revenue 2014
  • Exhibit 60: Teva Pharmaceuticals: Business segmentation by revenue 2013 and 2014
  • Exhibit 61: Teva Pharmaceuticals: Geographical segmentation by revenue 2014
Back to Top